Quick Answer
ENDONOVO THERAPEUTICS, INC. reported Cash and Equivalents of $85.9 thousand for fiscal year 2021.
ENDONOVO THERAPEUTICS, INC. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2021 | $85.9K | +540.4% |
| 2020 | $13.4K | -29.0% |
| 2019 | $18.9K | -95.0% |
| 2018 | $379.2K | +320.5% |
| 2017 | $90.2K | +62.4% |
| 2016 | $55.5K | +33.9% |
| 2015 | $41.5K | +4097.7% |
| 2014 | $988.00 | -69.6% |
| 2013 | $3.3K | -95.3% |
| 2011 | $69.7K | +100.5% |
| 2010 | $34.8K | -29.4% |
| 2009 | $49.2K | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2023 | $0.00 | -100.0% | -100.0% |
| June 30, 2023 | $32.6K | — | +198.0% |
| March 31, 2023 | $10.9K | -81.8% | +11065.3% |
| December 31, 2022 | $98.00 | -99.9% | -99.6% |
| September 30, 2022 | $23.1K | +303.7% | -61.4% |
| March 31, 2022 | $60.0K | -30.2% | -30.2% |
| December 31, 2021 | $85.9K | +540.4% | +1399.2% |
| September 30, 2021 | $5.7K | +121.9% | -32.9% |
- ENDONOVO THERAPEUTICS, INC. showed an increase of +540.4% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2009–2021 period, ENDONOVO THERAPEUTICS, INC.’s cash and equivalents has grown by 74.5% (from $49.2 thousand to $85.9 thousand).
- The most recent figure is from ENDONOVO THERAPEUTICS, INC.’s fiscal year 2021 report (Form 10-K), filed with the SEC on April 14, 2022.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: